Sign in Subscribe

article

A collection of 632 issues

Digital Platform Validated for Colorectal Cancer Risk Stratification and Personalized Screening Recommendations

Skip to content The CRC Digest Digital Platform Validated for Colorectal Cancer Risk Stratification and Personalized Screening Recommendations Validation study of ChequeáTuColon, a digital tool designed to stratify colorectal cancer risk, detect alarm symptoms, and provide personalized guideline-based screening recommendations, shows accuracy when compared to expert gastroenterologist assessments. (Digestive Diseases

Blood-Based Immune Profiling Identifies Circulating Th1-Like Cells as Biomarker for Advanced Adenomas

Skip to content The CRC Digest Blood-Based Immune Profiling Identifies Circulating Th1-Like Cells as Biomarker for Advanced Adenomas Prospective study of 104 FOBT-positive patients used spectral cytometry and machine learning to identify circulating Th1-like cells as a potential blood biomarker to improve detection of advanced colorectal adenomas and optimize colonoscopy

Structured Surveillance in Lynch Syndrome Shows Effectiveness and Identifies Unmet Needs

Skip to content The CRC Digest Structured Surveillance in Lynch Syndrome Shows Effectiveness and Identifies Unmet Needs Retrospective analysis of 517 Lynch syndrome carriers undergoing structured multiorgan surveillance over 4,827 person-years reports cancer incidence rates, tumor distribution, and modes of detection to assess adherence and effectiveness of guideline-based follow-up.

Immunotherapy Combination Achieves Complete Response and Polyp Regression in dMMR Colorectal Cancer

Skip to content The CRC Digest Immunotherapy Combination Achieves Complete Response and Polyp Regression in dMMR Colorectal Cancer Case report from the NOUS-209-01 trial describes a patient with mismatch repair-deficient colorectal cancer who achieved complete pathologic response and significant colonic polyp regression following treatment with Nous-209 plus pembrolizumab. (Journal of

Scoping Review Identifies Barriers to Diagnostic Colonoscopy After Positive Stool-Based Screening

Skip to content The CRC Digest ▪ SCREENING Scoping Review Identifies Barriers to Diagnostic Colonoscopy After Positive Stool-Based Screening Systematic review synthesizes barriers and facilitators to completing diagnostic colonoscopy after a positive non-invasive stool-based screening test (FIT, gFOBT, or multitarget stool DNA), emphasizing that timely follow-up colonoscopy is essential for reducing

Pooled Analysis Identifies Predictive Biomarkers for Cetuximab Rechallenge in Metastatic Colorectal Cancer

Skip to content The CRC Digest ◇ RESEARCH Pooled Analysis Identifies Predictive Biomarkers for Cetuximab Rechallenge in Metastatic Colorectal Cancer Pooled analysis of 180 patients from the CAVE and CAVE-2 studies investigates clinical variables that predict response to cetuximab rechallenge (with or without avelumab) in patients with circulating tumor DNA RAS/

HER2-Targeted Therapy Gains Ground in Metastatic Colorectal Cancer with New Treatment Sequencing Guidance

Skip to content The CRC Digest ▸ TREATMENT HER2-Targeted Therapy Gains Ground in Metastatic Colorectal Cancer with New Treatment Sequencing Guidance Narrative review outlines practical patient selection and treatment sequencing for HER2-targeted therapies in metastatic colorectal cancer, focusing on RAS wild-type disease with HER2 overexpression or ERBB2 amplification, including dual HER2

Extended Follow-Up Shows Durable Responses with Dual Immunotherapy in MSS Metastatic Colorectal Cancer Without Liver Metastases

Skip to content The CRC Digest ◆ TRIAL DATA Extended Follow-Up Shows Durable Responses with Dual Immunotherapy in MSS Metastatic Colorectal Cancer Without Liver Metastases Phase 1b trial of botensilimab (Fc-enhanced anti-CTLA-4) plus balstilimab (anti-PD-1) in patients with microsatellite-stable metastatic colorectal cancer and no active liver metastases reports extended follow-up data

Combination therapy targets KRAS G12C mutation in metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Combination therapy targets KRAS G12C mutation in metastatic CRC The Lancet Oncology published results showing encouraging antitumor activity of ifebemtinib combined with garsorasib in previously treated patients whose metastatic colorectal cancer harbors the KRAS G12C mutation. (The Manila Times) This content is informational

Age-stratified analysis reveals CEMIP elevation in early-onset CRC

Skip to content The CRC Digest ◇ RESEARCH Age-stratified analysis reveals CEMIP elevation in early-onset CRC Transcriptomic profiling identified CEMIP, NKD2, and FOXQ1 as elevated in colorectal cancer diagnosed before age 50, with CEMIP showing the strongest association with survival outcomes. (Genes) This content is informational only and does not constitute